The document provides an overview of the European Union's pharmaceutical regulatory system. It discusses the EU institutions responsible for pharmaceutical legislation, including the European Commission and European Medicines Agency (EMA). The EMA consists of scientific committees like CHMP and CVMP that are responsible for reviewing medicine applications and developing guidelines. National competent authorities within EU member states are responsible for approving medicines via decentralized and national procedures and providing expertise to EMA committees.
Clinical Research Regulation in European Union ShantanuThakre3
- On 16 April 2014, the European Commission adopted the new Clinical Trial Regulation (EU No 536/2014), repealing Directive 2001/20/EC.
- Although the Clinical Trial Regulation was adopted and entered into force in 2014, the timing of its application depends on confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit.
- The Regulation becomes applicable six months after the European Commission publishes notice of this confirmation.
Clinical Research Regulation in European Union ShantanuThakre3
- On 16 April 2014, the European Commission adopted the new Clinical Trial Regulation (EU No 536/2014), repealing Directive 2001/20/EC.
- Although the Clinical Trial Regulation was adopted and entered into force in 2014, the timing of its application depends on confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit.
- The Regulation becomes applicable six months after the European Commission publishes notice of this confirmation.
Annual report 2015 - European Directorate for the Quality of Medicines & Heal...Council of Europe (CoE)
This publication presents the work carried out in 2015 by the European Directorate for the Quality of Medicines & HealthCare, Council of Europe, highlighting its particular achievements.
Introduction to pharmaceutical regulatory agenciesDoaa Abouzeid
Regulatory authorities act as a guardian that ensures the safety, efficacy and quality of drugs available to the public.
They work to identify the strengths and weaknesses of drug regulation and to propose strategies to improve drug regulation.
The international regulatory organizations whether they are Governmental or Non-governmental play an essential role in all aspects of pharmaceutical regulations related to drug product registration, manufacturing, distribution, price control, marketing, research and development, and intellectual property protection.
Eu Regulatory & Quality Environment- Abhishek RavalAbhishekRaval16
Contains-
History, Geography, Political Equations, Type of Procedures, DE& ME, All Regulatory Procedures incl. PLCM, Pharmacovigilance, GMP Insights, Control of API, Supply Chain, Various Fees, Discussion on Pro's & Con's Of MAH vs CMO model business.
Annual report 2015 - European Directorate for the Quality of Medicines & Heal...Council of Europe (CoE)
This publication presents the work carried out in 2015 by the European Directorate for the Quality of Medicines & HealthCare, Council of Europe, highlighting its particular achievements.
Introduction to pharmaceutical regulatory agenciesDoaa Abouzeid
Regulatory authorities act as a guardian that ensures the safety, efficacy and quality of drugs available to the public.
They work to identify the strengths and weaknesses of drug regulation and to propose strategies to improve drug regulation.
The international regulatory organizations whether they are Governmental or Non-governmental play an essential role in all aspects of pharmaceutical regulations related to drug product registration, manufacturing, distribution, price control, marketing, research and development, and intellectual property protection.
Eu Regulatory & Quality Environment- Abhishek RavalAbhishekRaval16
Contains-
History, Geography, Political Equations, Type of Procedures, DE& ME, All Regulatory Procedures incl. PLCM, Pharmacovigilance, GMP Insights, Control of API, Supply Chain, Various Fees, Discussion on Pro's & Con's Of MAH vs CMO model business.
This publication presents an overview of the Products and Services available in 2016 from the European Directorate for the Quality of Medicines & HealthCare, Council of Europe.
Pharmacopoeia: the word derives from the ancient Greek word pharmakon means drug & poeia- to make.
It is a legally binding collection, prepared by a national or regional authority& contains list of medicinal substances, crude drug & formulas for making preparation from them.
It a detailed description of European Union and Medicines and Healthcare Products Regulatory agency with documentation process of filing MAA application.
European medicine agency is one of the finest agency to check the quality, efficacy ,safety of a drug in all European countries . It consists of 27 states of Europe as its member.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Francesca Gottschalk - How can education support child empowerment.pptxEduSkills OECD
Francesca Gottschalk from the OECD’s Centre for Educational Research and Innovation presents at the Ask an Expert Webinar: How can education support child empowerment?
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
1. GUIDED BY:-
Dr. RAJESH K S
Principle
PREPARED BY:-
DINESH KUMAR
M.Pharm.:-3nd Sem. QA.
IST Shift
Enroll. No.:- 132330804003
1
2. Table of content
The European Union – In Perspective
The EU Today
The EU – Areas of Responsibility
Responsible EU Institutions
EU Pharmaceutical Legislation
Why is There EU Pharmaceutical Legislation?
What is a Competent Authority in the European
Union?
Responsibilities of the Competent Authorities
EMEA Scientific Committees
CHMP,CVMP,COMP,HMPC,PDCO,CAT & PRAC.
CHMP Working Parties
Current CHMP Scientific Advisory Groups (SAG)
European Medicines Network
Routes to License in the EU and its Member States
3. Centralized Procedure
Mutual Recognition
Decentralized Procedure
The European Directorate for the Quality of
Medicines and Healthcare (EDQM)
INDIAN PHARMACEUTICAL REGULATORY
ENVIRONMENT
Their regulatory bodies
References
3
4. The European Union– In Perspective
Began in the 1950s as the European Economic
Community (EEC) with six founding members
Belgium
Germany
France
Italy
Luxembourg
The Netherlands(1)
4
5. The EU Today
EU Member States comprise 28 countries and a total
population of 501,259,840 (Eurostat 8 Jan 2010)
Austria Hungary Slovakia
Belgium Ireland Slovenia
Bulgaria Italy Spain
Cyprus Latvia Sweden
Czech republic Lithuania U.K
Denmark Luxembourg
Estonia Malta
Finland Netherland
France Poland
Germany Portugal
Greece Romania (1)
5
8. The EU – Areas of Responsibility
European union(EU) responsible for legislating
and enforcing laws in all industries (including
pharmaceutical and medical devices)
Finance
Energy
Environment
Transportation
Public health
Regional policy
Indirect taxation
Agriculture
Fisheries(1)
8
9. Responsible EU Institutions
European Commission
Executive Branch
Drafting of legislative proposals
Represents the “community”
Organized into Directorates General
European Council
Senior members (heads of State or ministers)
Represents Member States
European Parliament
Elected officials
Represents the “citizenry”
EU Courts(1)
9
10. EU Pharmaceutical Legislation
Directive 2001/83EC: Community on
Medicinal Products for Human Use
No medicinal products may be placed on the
market of a Member State.
unless an authorization has been issued by the
competent authorities of that Member State or by
the European Medicines Agency (EMA).
An authorization holder may submit a request for
recognition of this authorization to other Member
States.(1)
10
11. Regulation (EC) 726/2004: Centralized
procedure and the functioning of the
European Medicines
The European Parliament and the Council of a
centralized Community procedure for the
authorization of medicinal products.
which there is a single application, a single
evaluation and a single authorization allowing
direct access to the single market of the
community.(1)
11
12. Why is There EU Pharmaceutical Legislation
Safeguard the Public Health
Improve Functioning of the Internal Market
Establish uniform rules for the performance of
tests and
Trials on medicines to ensure therapeutic efficacy
Provide faster access to innovative products
Boost competiveness of EU-based Pharmacy
industry
Meet challenges of the global marketplace(1)
12
13. What is a Competent Authority in the EuropeanUnion?
Any organization within a Member State (MS) with
legally delegated authority or power to perform a
designated function
That function can be in one of numerous
commercial areas, for example:
Human medicines
Veterinary medicines
Medical devices
Blood transfusion services
Consumer products
Food(2)
13
14. Within the Member States of the European
Union Case have very different structures and
organizations:
Some MS have separate CA for human and
veterinary medicines (e.g. UK, France and
Hungary)
Some MS have a single CA for human and
veterinary medicines(e.g. Netherlands and
Ireland)
Some MS have separate CA for small
molecule based medicines and biologically
based medicines (e.g. Germany)
Currently there are 48 Competent Authorities
which support the EMA.(2)
14
15. Responsibilities of the CompetentAuthorities
Primary responsibilities of CA include:
License for human and veterinary medicinal
products via the National (MS) and Decentralized
routes
Performing good practice inspections
Pharmacovigilance
Providing expert resource to the EMA, such as:
Membership of EMA Scientific Committees (CHMP,
CVMP, COMP, PDCO, etc.)
Membership of CHMP Working Parties (Currently
12 ‘Permanent’ + 1 Temporary)
Membership of Scientific Advisory Groups (SAGs)
Acting as Reporter / Co-Reporter for Centralized
Marketing Authorization Applications(2)
15
16. Acting as Reference Member State for Mutual
Recognition Applications
Acting as Reference Member State for
Decentralized Marketing Authorization
Applications(2)
16
17. EMEAScientificCommittees
CHMP - Committee for Medicinal Products for
Human Use
CVMP - Committee for Medicinal Products for
Veterinary Use
COMP - Committee for Orphan Medicinal Products
PDCO - Pediatric Committee
CAT - Committee for Advanced Therapies
HMPC - Committee on Herbal Medicinal Products
PRAC – Pharmacovigilance Risk Assessment
Committee (4)
17
18. CHMP - Committee for Medicinal Productsfor Human Use
Composition
The members and alternates of the CHMP are
nominated by European Union Member States in
consultation with the Agency's Management
Board.
They serve on the Committee for a renewable
period of three years.
The CHMP is composed of:
a chairman, elected by serving CHMP members;
one member and an alternate nominated by each
of the 28 Member States;
one member and an alternate nominated by
Iceland and by Norway;
up to five co-opted members nominated by
Member States or the Agency.(4)
18
19. Function
responsible for preparing opinions on questions
concerning medicines for human use.
Developing a new medicinal products.
The preparation of scientific and regulatory
guidelines for the pharmaceutical industry.
Cooperation with international partners on the
harmonization of regulatory requirements for
medicines.(4)
19
20. CVMP - Committee for Medicinal Products for Veterinary Use
Composition
The members and alternates of the CVMP are nominated
by the European Union Member States, in consultation
with the Agency's Management Board.
They serve on the Committee for a renewable period of
three years.
The CVMP is composed of:
a chairman, elected by serving CVMP members;
one member and an alternate nominated by each of the
28 Member States;
one member and an alternate nominated by Iceland and
by Norway;
up to five co-opted members nominated by Member
States or the Agency.
Function
responsible for preparing opinions on questions
concerning medicines for veterinary use.(4)
20
21. COMP- Committee for OrphanMedicinal Products
This designation is for medicines to be developed
for the diagnosis, prevention or treatment of rare
diseases that are life-threatening or very
serious.
Composition
The members of the COMP are nominated by
the EU Member States, in consultation with the
Agency's Management Board.
Six members are nominated by the European
Commission (To represent patient organizations).
All members serve on the Committee for a
renewable period of three years.(4)
21
22. The COMP is composed of:
a chair, elected by serving COMP members;
one member nominated by each of the 28 Member
States;
three members nominated by the European
Commission to represent patients' organizations;
three members nominated by the European
Commission on the Agency's recommendation;
one member nominated by Iceland and one by
Norway.
Function
responsible for reviewing applications from people
or companies seeking 'orphan-medicinal-product
designation'.(4)
22
23. PDCO- PediatricCommittee
The PDCO was established in accordance with the
Paediatric Regulation (Regulation (EC) 1901/2006 as
amended).
The members of the PDCO are appointed for a renewable
period of three years.
Composition
The PDCO is composed of
The chair is elected from its members.
five members appointed by the CHMP itself;
one member and one alternate appointed by each
European Union (EU) Member State
three members and alternates representing healthcare
professionals;
three members and alternates representing patient
associations
Function
responsible for assessing the content of pediatric
investigation plans.(4)
23
24. CAT - Committee for Advanced Therapies
It was established in accordance with Regulation (EC)
No 1394/2007 on ATMPs.
Composition
The members of the CAT are appointed for a renewable
period of three years.
The chair and vice-chair are elected from its members
for a term of three years, which may be renewed once.
The CAT is composed of:
five members appointed by the CHMP itself;
one member and one alternate appointed by each
European Union (EU) Member State
two members and two alternates appointed by the
European Commission to represent clinicians;
two members and two alternates appointed by the
European Commission to represent patient associations.
Function
responsible for assessing the quality, safety and efficacy
of advanced-therapy medicinal products (ATMPs) and
following scientific developments in the field.(4) 24
25. HMPC - Committee on Herbal Medicinal Products
It was established in September 2004, replacing the
Committee for Proprietary Medicinal Products.
Composition
The members of the HMPC are scientific experts in the field
of herbal medicines.
One member and one alternate member nominated by
each of the 28 EU Member States and by Iceland and
Norway.
The chair is elected by serving HMPC members.
Up to five additional members nominated by the Member
States or by the Agency. The members are expertise in;
clinical pharmacology;
experimental / non-clinical pharmacology;
toxicology;
pediatric medicine;
general and family medicine.
Function
responsible for preparing the Agency's opinions on herbal
medicines.(4)
25
26. PRAC – Pharmacovigilance Risk Assessment Committee
The PRAC's recommendations are considered by the
Committee for Medicinal Products for Human Use
(CHMP)
Composition
The members and alternates of the PRAC are
nominated by European Union Member States, in
consultation with the Agency's Management Board.
The European Commission also appoints six
independent scientific experts.
All serve on the Committee for a period of three
years which is renewable once.(4)
26
27. The PRAC is composed of:
a chair and a vice chair, elected by serving PRAC
members;
one member and an alternate nominated by each of
the 28 Member States;
one member and an alternate nominated by Iceland
and by Norway;
one member and an alternate nominated by the
European Commission to represent healthcare
professionals;
one member and one alternate nominated by the
European Commission to represent patients
organizations.
Function
responsible for assessing and monitoring safety
issues for human medicines.(4)
27
28. CHMP Working Parties
Biologics Working Party (BWP)
Blood Products Working Party (BPWP)
Cell-based Products Working Party (CPWP)
Efficacy Working Party (EWP)
Gene Therapy Working Party (GTWP)
Joint CHMP/CVMP Quality Working Party (QWP)
Patients' and Consumers' Working Party (PCWP)
Phamacogenomics Working Party (PgWP)
Pharmacovigilance Working Party (PhVWP)
Safety Working Party (SWP)
Scientific Advice Working Party (SAWP)
Vaccine Working Party (VWP)
Similar Biological Medicinal Products Working
Party (BMWP)
SAWP - The Scientific Advice Working Party(3)
28
29. EuropeanMedicines Network
CA form one part of what is known as the
European Medicines Network
This network includes:
The EMA, as the overall coordinator of existing
scientific resources in the MS
The CAs (> 40)
The list of European Experts
European Directorate for the Quality of Medicines
and Healthcare (EDQM)
Official Medicines Control Laboratories (OMCLs) in
Member States(3)
29
30. Routes to License in the EU and its Member States
Centralized Procedure
Mutual Recognition
Decentralized Procedure (1)
30
31. CentralizedProcedure
Managed solely through the CHMP
One Marketing Authorization covering all MS & EEA
issued by the EU Commission
o The Centralized Procedure is mandatory for certain
products and issues:
New products and therapeutic classes (e.g., AIDs,
cancer, neurodegenerative disorder, diabetes,
autoimmune diseases and viral diseases)
Medicinal products manufactured by a biotech
process such as:
Recombinant DNA technology
Controlled expression of genes coding for active
proteins
Hybridoma and monoclonal antibody methods(1)
31
33. Mutual Recognitionand DecentralizedSystems
Both pathways essentially governed by one
Directive
Pathways used for:
New active substance (if not obliged to file
centrally)
Line extensions to existing Mutual Recognition
products
Generic applications (for nationally and centrally
authorized reference products)
New combinations of known actives
By consent applications
Well established use products
Homeopathic and herbals
33
34. How to determine the pathway
Mutual Recognition – when your product already
has a Market Authorization in a Member State
Decentralized – when your product does not yet
have a Market Authorization in a Member State(1)
34
35. The European Directoratefor the Qualityof Medicines and Healthcare
(EDQM)
EDQM is involved in medicines control, including
laboratory facilities, at a wider European level
The Council of Europe this work co-ordinates
activities in 47 countries
These activities include:
Responsibility for the European Pharmacopoeia
Co-ordinating the OMCL network
Co-ordinating other medicines control activities
via national agencies, inspectorates etc.
Operation of the Certificates of Suitability
Blood Transfusion and Organ Transplantation
Pharmaceuticals and Pharmaceutical Care(1)
35
36. INDIANPHARMACEUTICALREGULATORY ENVIRONMENT
The principal regulatory body involved in the
approval of manufacture, drug development and
marketing of quality drugs in India.
The Central Drug Standards and Control
Organization (CDSCO) under Ministry of Health
and Family Welfare which works on developing
standards and measures for ensuring the safety,
efficacy and quality of drugs, cosmetics,
diagnostics and devices in the country.
It regulates the market authorization of new drugs
and clinical trials standards; supervises drug
imports and approves licenses to manufacture the
products.
At the state level, state drug regulatory authority
issues licences to manufacture approved drugs and
to monitor the quality of drugs along with
CDSCO.(5)
36
37. The regulatory bodies involved in the
pharmaceutical industry and their functions are as
follows:
Drugs Control General of India (DCGI )- Main
authority for clinical trials, ensures standards,
registers all imported drugs, new drugs, biologics
and medical devices.
Indian Council of Medical Research (ICMR)-
main center for biomedical research.
Genetic Engineering Approval Committee
(GEAC)- deals with genetic engineering and
molecular biology, trials in which biotech products
are used will be referred here by DCGI.
Department of Biotechnology (DBT)-oversees
the development of modern biology and
biotechnology in India.
Atomic Energy Review Board (AERB)- has
regulatory control over radiation equipment.
Baba Atomic Research Centre (BARC)-
approves all radiation related projects and radio
pharmaceuticals in India.(5) 37
38. GOVT. OF INDIA
38
Ministry of
health &family
weifare
Ministry of
chemicals
&fertilizers
Ministry of
commerse
Ministry of
science &
technology
DGHS Dept. of
Pharmaceuticals
Patent office ICMR
DCGI NPPA Controller general
of patents
DBT
DTAB CSIR
CDSCO
39. Drugs Consultative Committee (DCC)-
provides technical guidance to the CDSCO.
Central Drugs Laboratory (CDL)-maintains
quality control of drugs
Central License Approving Authority (CLAA)-
provides approval for manufacturing licenses’
Drugs Technical Advisory Board (DTAB) –
Provides technical guidance to the CDSCO
National Pharmaceutical Pricing Authority
(NPPA)- NPPA fixes or revises the prices of
decontrolled bulk drugs and formulations and
periodically updates the list under price control
according to guidelines.(5)
39
40. References
1. joel.falk@weinberggroup.com
2. The Council of the European Union, press
release, 14 April 2014
3. http://europa.eu.int/eur-lex
4. shttp://www.emea.eu.int/index/-indexh1.htm
5. http://www.jli.edu.in/blog/trends-of-the-indian-
pharmaceutical-regulatory-system
40